Table of Contents Table of Contents
Previous Page  488 / 812 Next Page
Information
Show Menu
Previous Page 488 / 812 Next Page
Page Background

S484

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805

Conclusions

MBAT can be seen as an effective treatment method

that improves breast cancer patients’ psychological stability and

quality of life. Evaluation of treatment effects using program devel-

opment and large-scale research for future clinical application is

needed.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1409

EV425

Psychosocial outcomes 3 years after

facial transplantation of a blind

patient

G. Lemmens

1 ,

, H. Hendrickx

2

, C. Poppe

3

, N. Roche

4

, P. Peeters

5

,

H. Vermeersch

6

, X. Rogiers

3

, K. Van Lierde

7

, P. Blondeel

4

1

Ghent university, psychiatry and medical psychology, Ghent,

Belgium

2

Ghent university hospital, burn unit, Ghent, Belgium

3

Ghent university hospital, department of general and hepato-biliary

surgery and transplantation- transplantation centre, Ghent, Belgium

4

Ghent university hospital, department of plastic and reconstructive

surgery, Ghent, Belgium

5

Ghent university hospital, department of nephrology, Ghent,

Belgium

6

Ghent university hospital, department of head and neck and

maxilo-facial surgery, Ghent, Belgium

7

Department of speech, language and hearing science, Ghent,

Belgium

Corresponding author.

Background

To date, psychosocial outcomes after facial trans-

plantation are promising although long-term consequences,

outcome of blind patients and the impact on family members are

less well investigated. The aim of this study was to examine the

long-term psychosocial of a blind patient and his partner 2 and 3

years after facial transplantation.

Methods

Depressive and anxiety symptoms, hopelessness, cop-

ing, resilience, illness cognitions, marital support, dyadic adjust-

ment, family functioning and quality of life of the patient and the

partner were assessed before and 2 and 3 years after transplanta-

tion. Reliable change index (RCI) was further calculated to evaluate

the magnitude of change.

Results

Most psychological, marital and family scores of both the

patient and the partner remained within a normative and healthy

range at follow-up. Resilience (RCI: 2.5 & 3.4 respectively), affective

responsiveness (RCI:

4.1 &

3.2 respectively), physical quality of

life (RCI: 8.7 & 7.2 respectively) and helplessness (RCI:

2.2 &

2.9

respectively) of the patient improved at 2 and 3 years follow-up.

Further, dyadic cohesion (RCI: 2.4) of the patient improved at 2

years whereas marital depth (RCI:

2.0) of the partner decreased

at 3 years.

Conclusions

The results of this study point to positive long-term

psychosocial outcomes of a blind patient and his partner after facial

transplantation. Further, they may underscore the importance of

patient selection, social support and involvement of family mem-

bers in treatment.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1410

EV426

Alternative treatment options for

lithium-induced nephrogenic

diabetes insipidus

S. López-Romeo

, G. Ledesma-Iparraguirre

Parc Sanitari Sant Joan de Déu, psychiatry, Barcelona, Spain

Corresponding author.

Introduction

Lithium is currently a drug of choice for treating per-

sons with bipolar disorder and is widely used in this population.

Approximately, 30% of patients taking lithium experience at least

one episode of lithium toxicity. Treatment of acute toxicity involves

correction of electrolyte abnormalities, volume repletion followed

by forced diuresis, and dialysis in severe cases. A case report is

described and it is reviewed some alternative treatment options

before considering withdrawal of lithium treatment in lithium-

induced nephrogenic diabetes insipidus.

Case report

A 58-year-oldwoman diagnosed of hypertension and

bipolar disorder for 20 years. At first, she was controlled with val-

proic acid until she suffered a manic episode which required a

mood stabilizer switch. She started a treatment with lithium 1200

mg/day and olanzapine to 10 mg/day and was completely recov-

ered. After a year of stabilization, olanzapine was retired and she

maintained stabilized with lithium 1000 mg/day during last 17

years. During last 8 months, she suffered polydipsia and polyuria

(4 L/day). She was diagnosed of nephrogenic diabetes insipidus.

Some measures like liquid restriction, lithium monodose and low

sodium diet were carried out, obtaining a partial response. Tak-

ing into account, she was stabilised with lithium for many years,

it was decided to introduce hydrochlorothiazide 25 mg/day, clini-

cal and analytical resolution of nephrogenic diabetes insipidus was

obtained. A year later, she maintains psychopathological stabiliza-

tion, without any lithium secondary effects.

Conclusion

Some treatment options for lithium-induced nephro-

genic diabetes insipidus could be introducing thiazides, amiloride,

indomethacin, desmopressin or carbamazepine, instead of with-

drawal lithium.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.1411

EV427

New interferon-free therapies on

HCV+ chronic hepatitis: Overcoming

psychiatric side effects in a real world

setting

M. Moneglia

1 ,

, A. Santangelo

1

, A. Ballerini

1

, V. Ricca

1

,

A.L. Zignego

2

1

Azienda Ospedaliero-Universitaria Careggi, department of

neuroscience- psychology- drug research and child health, Florence,

Italy

2

Azienda Ospedaliero-Universitaria Careggi, center for systemic

manifestations of hepatitis viruses MASVE- department of

experimental and clinical medicine, Florence, Italy

Corresponding author.

Introduction

Interferon-alpha (IFN ) was the backbone therapy

for HCV+ related chronic hepatitis (CH-C). However, it was asso-

ciated with significant neuropsychiatric side effects and impaired

health-related quality of life. Second Generation IFN -free direct-

acting antiviral agents (DAAs) seem to be associated with fewer

side effects, better tolerability, high efficacy rates and better patient

reported outcomes (PROs) [Younoussi, 2014].

Aims

To describe the neuropsychiatric symptoms and PROs dur-

ing SecondGenerationDAAs plus ribavirin oral treatment in a group

of CH-C real world patients.

Methods

Nineteen CH-C outpatients, scheduled for IFN -free

treatment, were assessed at enrolment (T0), at 4 (T1) and at 12 (T2)

weeks, the end of treatment, by means of MDRS, HAM-D, HAM-

A, MRS, Y-BOCS and SF-36. A pharmacological therapy, based on

clinical evidence, was provided at psychiatric symptoms onset.

Results

During the treatment, we didn’t report any worsening in

the administred psychometric scales. Furthermore, we observed a

general improvement at week 12 (T2), statistically significant only

for MRS (

P

< 0.05). Any statistically significant difference was found

for SF-36 mean scores comparing T0, T1 and T2. However, SF-36